001     281738
005     20251013100247.0
024 7 _ |a 10.1177/13872877251371729
|2 doi
024 7 _ |a pmid:40899930
|2 pmid
024 7 _ |a 1387-2877
|2 ISSN
024 7 _ |a 1875-8908
|2 ISSN
037 _ _ |a DZNE-2025-01171
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Špeh, Andreja
|b 0
245 _ _ |a Cardiovascular health and cognition in older adults: Variations across recruitment models and European countries in the MOPEAD project.
260 _ _ |a Amsterdam
|c 2025
|b IOS Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1760342422_8169
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a BackgroundThe Models of Patient Engagement for Alzheimer's Disease (MOPEAD) project aimed to identify the most effective and cost-efficient recruitment model for detecting prodromal and mild Alzheimer's disease (AD) across five European countries.ObjectiveTo examine differences in cardiovascular risk factors and cognitive performance among countries and recruitment models using MOPEAD data.MethodsIndividuals aged 65-85 with a high risk for prodromal or mild AD were included. Four recruitment models were used: a web-based screening tool, an open house initiative (OHI), a primary care-based protocol for early detection of cognitive decline, and a tertiary care-based screening at a diabetologist clinic. Participants from Germany, Spain, the Netherlands, Sweden, and Slovenia were recruited. Cardiovascular risk factors were self-reported, and cognition was assessed using The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).ResultsA total of 414 individuals (mean age 71.9, SD = 5.0) were included. Significant differences were observed in physical activity (p < 0.001), with individuals from Sweden and Slovenia being the most active. Dutch participants scored highest on most cognitive measures. Individuals recruited via web-based survey were youngest, most active (61.7%), and had the lowest rates of diabetes (12.0%) and heart disease (6.4%), as well as the best cognitive scores. Those recruited via diabetologist clinics displayed the highest cardiovascular risk and the lowest cognitive performance.ConclusionsThis study unveils significant disparities in cardiovascular health and cognition across recruitment strategies and European countries. The OHI shows promise for future recruitment in the context of disease-modifying AD treatments.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alzheimer's disease
|2 Other
650 _ 7 |a cardiovascular health
|2 Other
650 _ 7 |a cognition
|2 Other
650 _ 7 |a cross-country
|2 Other
650 _ 7 |a early diagnosis
|2 Other
650 _ 7 |a participants recruitment
|2 Other
700 1 _ |a Boada, Merce
|b 1
700 1 _ |a Jessen, Frank
|0 P:(DE-2719)2000032
|b 2
|u dzne
700 1 _ |a Visser, Pieter Jelle
|b 3
700 1 _ |a Winblad, Bengt
|b 4
700 1 _ |a Wimo, Anders
|b 5
700 1 _ |a Sannemann, Lena
|b 6
700 1 _ |a Stopar, Nina
|b 7
700 1 _ |a Zwan, Marisa
|b 8
700 1 _ |a Rodriguez-Gomez, Octavio
|b 9
700 1 _ |a Johansson, Gunilla
|b 10
700 1 _ |a Alegret, Montse
|b 11
700 1 _ |a Rodríguez, Isabel
|b 12
700 1 _ |a Gurrutxaga, Miren
|b 13
700 1 _ |a Sotolongo, Oscar
|b 14
700 1 _ |a Ruiz, Agustin
|b 15
700 1 _ |a Cantero-Fortiz, Yahveth
|b 16
700 1 _ |a Kramberger, Milica Gregorič
|b 17
773 _ _ |a 10.1177/13872877251371729
|g p. 13872877251371729
|0 PERI:(DE-600)2070772-1
|n 4
|p 1530 - 1538
|t Journal of Alzheimer's disease
|v 107
|y 2025
|x 1387-2877
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2000032
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-20
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-20
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-20
920 1 _ |0 I:(DE-2719)1011102
|k AG Jessen
|l Clinical Alzheimer’s Disease Research
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1011102
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21